Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | HTR2C | P28335 | 6/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957811 | 0.86 | HTR2A (0.55) | HTR2AHTR2CHTR2BSLC6A4KCNH2 | |
| SCHEMBL22957894 | 0.85 | RIPK1 (0.48) | NPY1RNPY2RRIPK1HTR2AHTR2C | |
| SCHEMBL22391953 | 0.84 | RIPK1 (0.61) | RIPK1HTR2AHTR2CHTR2BRBP4 | |
| SCHEMBL22957672 | 0.83 | RIPK1 (0.60) | NPY1RNPY2RRIPK1HTR2CMEN1 | |
| SCHEMBL22957846 | 0.83 | NPY1R (0.70) | NPY1RNPY2RRIPK1MEN1KMT2A | |
| SCHEMBL24224753 | 0.81 | HTR2A (0.54) | RIPK1HTR2AHTR2CHTR2BPKM | |
| SCHEMBL22957816 | 0.81 | RIPK1 (0.60) | NPY1RNPY2RRIPK1HTR2CMEN1 | |
| SCHEMBL29786347 | 0.79 | HTR2C (0.52) | RIPK1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL20472535 | 0.79 | HTR2C (0.52) | RIPK1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL22957702 | 0.79 | RIPK1 (0.40) | NPY1RNPY2RRIPK1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | NPY1R 2919/4885NPY2R 3582/4885RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.